503 related articles for article (PubMed ID: 14581367)
1. Reduced ING1b gene expression plays an important role in carcinogenesis of non-small cell lung cancer patients.
Kameyama K; Huang CL; Liu D; Masuya D; Nakashima T; Sumitomo S; Takami Y; Kinoshita M; Yokomise H
Clin Cancer Res; 2003 Oct; 9(13):4926-34. PubMed ID: 14581367
[TBL] [Abstract][Full Text] [Related]
2. Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients.
Liu D; Huang CL; Kameyama K; Hayashi E; Yamauchi A; Sumitomo S; Yokomise H
Cancer; 2002 Apr; 94(8):2239-47. PubMed ID: 12001123
[TBL] [Abstract][Full Text] [Related]
3. Alterations in novel candidate tumor suppressor genes, ING1 and ING2 in human lung cancer.
Okano T; Gemma A; Hosoya Y; Hosomi Y; Nara M; Kokubo Y; Yoshimura A; Shibuya M; Nagashima M; Harris CC; Kudoh S
Oncol Rep; 2006 Mar; 15(3):545-9. PubMed ID: 16465410
[TBL] [Abstract][Full Text] [Related]
4. Deregulated expression of c-mos in non-small cell lung carcinomas: relationship with p53 status, genomic instability, and tumor kinetics.
Gorgoulis VG; Zacharatos P; Mariatos G; Liloglou T; Kokotas S; Kastrinakis N; Kotsinas A; Athanasiou A; Foukas P; Zoumpourlis V; Kletsas D; Ikonomopoulos J; Asimacopoulos PJ; Kittas C; Field JK
Cancer Res; 2001 Jan; 61(2):538-49. PubMed ID: 11212247
[TBL] [Abstract][Full Text] [Related]
5. Survivin gene expression is negatively regulated by the p53 tumor suppressor gene in non-small cell lung cancer.
Nakano J; Huang CL; Liu D; Ueno M; Sumitomo S; Yokomise H
Int J Oncol; 2005 Nov; 27(5):1215-21. PubMed ID: 16211215
[TBL] [Abstract][Full Text] [Related]
6. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis.
Dosaka-Akita H; Hu SX; Fujino M; Harada M; Kinoshita I; Xu HJ; Kuzumaki N; Kawakami Y; Benedict WF
Cancer; 1997 Apr; 79(7):1329-37. PubMed ID: 9083154
[TBL] [Abstract][Full Text] [Related]
7. Genetic alterations of tumor suppressor ING1 in human non-small cell lung cancer.
Luo ZG; Tang H; Li B; Zhu Z; Ni CR; Zhu MH
Oncol Rep; 2011 Apr; 25(4):1073-81. PubMed ID: 21286670
[TBL] [Abstract][Full Text] [Related]
8. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
9. [Clinicopathological study on primary lung cancer--immunohistochemical expression of p53 suppressor gene and bcl-2 oncogene in relation to prognosis].
Irie K; Ishida H; Furukawa T; Koyanagi K; Miyamoto Y
Rinsho Byori; 1996 Jan; 44(1):32-41. PubMed ID: 8691638
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
Wen SF; Xie L; McDonald M; DiGiacomo R; Chang A; Gurnani M; Shi B; Liu S; Indelicato SR; Hutchins B; Nielsen LL
Cancer Gene Ther; 2000 Nov; 7(11):1469-80. PubMed ID: 11129289
[TBL] [Abstract][Full Text] [Related]
11. p53 mutations and p53, Waf-1, Bax and Bcl-2 expression in field cancerization of the head and neck.
Lavieille JP; Gazzeri S; Riva C; Reyt E; Brambilla C; Brambilla E
Anticancer Res; 1998; 18(6B):4741-9. PubMed ID: 9891551
[TBL] [Abstract][Full Text] [Related]
12. Altered subcellular localization and low frequency of mutations of ING1 in human brain tumors.
Vieyra D; Senger DL; Toyama T; Muzik H; Brasher PM; Johnston RN; Riabowol K; Forsyth PA
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5952-61. PubMed ID: 14676120
[TBL] [Abstract][Full Text] [Related]
13. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
[TBL] [Abstract][Full Text] [Related]
14. The candidate tumor suppressor ING1b can stabilize p53 by disrupting the regulation of p53 by MDM2.
Leung KM; Po LS; Tsang FC; Siu WY; Lau A; Ho HT; Poon RY
Cancer Res; 2002 Sep; 62(17):4890-3. PubMed ID: 12208736
[TBL] [Abstract][Full Text] [Related]
15. P21 gene expression as an indicator for the activity of adenovirus-p53 gene therapy in non-small cell lung cancer patients.
Boulay JL; Perruchoud AP; Reuter J; Bolliger C; Herrmann R; Rochlitz C
Cancer Gene Ther; 2000 Sep; 7(9):1215-9. PubMed ID: 11023193
[TBL] [Abstract][Full Text] [Related]
16. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
[TBL] [Abstract][Full Text] [Related]
17. Analyses of the tumour suppressor ING1 expression and gene mutation in human basal cell carcinoma.
Chen B; Campos EI; Crawford R; Martinka M; Li G
Int J Oncol; 2003 Apr; 22(4):927-31. PubMed ID: 12632089
[TBL] [Abstract][Full Text] [Related]
18. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
[TBL] [Abstract][Full Text] [Related]
19. The HAUSP gene plays an important role in non-small cell lung carcinogenesis through p53-dependent pathways.
Masuya D; Huang C; Liu D; Nakashima T; Yokomise H; Ueno M; Nakashima N; Sumitomo S
J Pathol; 2006 Apr; 208(5):724-32. PubMed ID: 16450335
[TBL] [Abstract][Full Text] [Related]
20. A novel molecular staging protocol for non-small cell lung cancer.
Miyake M; Adachi M; Huang C; Higashiyama M; Kodama K; Taki T
Oncogene; 1999 Apr; 18(14):2397-404. PubMed ID: 10327061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]